For example, the reduced risk of hypoglycemia was more significant (at month 6) in the EDITION 2 trial versus the EDITION 1 trial (it may be likely that the use of fast-acting analogue insulin in the EDITION 1 trial has impacted the difference found in the reduced risk of hypoglycemia between both trials). The gene discussed is INS; the disease is Hypoglycemia.